Pioglitazone and Heart Failure: Results From a Controlled Study in Patients With Type 2 Diabetes Mellitus and Systolic Dysfunction

2008 ◽  
Vol 14 (6) ◽  
pp. 335-335
Author(s):  
Scott Harris ◽  
David Tepper ◽  
Randy Ip
Keyword(s):  
Diabetes Mellitus ◽  
Heart Failure ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Systolic Dysfunction ◽  
Controlled Study

Pioglitazone and Heart Failure: Results From a Controlled Study in Patients With Type 2 Diabetes Mellitus and Systolic Dysfunction

2008 ◽  
Vol 14 (6) ◽  
pp. 445-452 ◽  
Author(s):  
Thomas D. Giles ◽  
Alan B. Miller ◽  
Uri Elkayam ◽  
Mondira Bhattacharya ◽  
Alfonso Perez
Keyword(s):  
Diabetes Mellitus ◽  
Heart Failure ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Systolic Dysfunction ◽  
Controlled Study

P2636Stage B predictors of non-ischemic heart failure in type 2 diabetes mellitus

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
A Klabnik ◽  
J Murin
Keyword(s):  
Diabetes Mellitus ◽  
Heart Failure ◽  
Atrial Fibrillation ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Left Atrial ◽  
Systolic Dysfunction ◽  
Left Atrial Enlargement ◽  
Atrial Enlargement

Abstract Purpose Stage B heart failure (SBHF), defined as LV hypertrophy (LVH) and impaired ejection fraction (EF), is precursor of reduced (HFrEF), mid-range (HFmrEF) or preserved (HFpEF) heart failure in type 2 diabetes mellitus (T2DM). Left atrial enlargement (LAE) and left ventricular diastolic or systolic dysfunction (assessed with tissue doppler and speckle-tracking echocardiography) are not accepted as HF stage B equivalents. Methods 396 consecutive community-based elderly (≥65 years) patients (pts) with asymptomatic T2DM (age 76±4 years; 64% women) with preserved EF (≥40%) and no atrial fibrillation, ischemic or valvular heart disease referred to echolab and prospectively followed from January 2015 by regional cardiologist. Results Prevalence of SBHF was observed in 6% after 2 years (EF≤40%) and LVH have 13% at baseline and 20% pts after 2 years. Left atrial enlargement (>34 ml/m2) occurs in 31%, resp. 48% pts after 24 months, diastolic dysfunction (E/e' >14) in 42%, resp. 68%. Systolic dysfunction (S' ≤6.0 cm/s) was observed in 20%, resp. 33% pts, and reduced global longitudinal (GLS <16%) in 23%, resp. 40% pts (all p<0.001). After a mean follow-up of 31±4 months developed new HF 19% pts (1% HFrEF, 6% HFmrEF and 12% HFpEF). The strongest predictors of incident HFpEF were older age (15%, 45% among men and 20%, 60% among women ages 65–74, and 75–85 years, p<0.001), new-onset atrial fibrillation: hazard ratio (HR) 1.4, p<0.01, and NTproBNP >125 pg/ml (HR 2,8, p<0.001). Significant (p<0.001) echocardiografic predictors of incident HFpEF were LVH (HR 2.90), systolic dysfunction (S' ≤6.0 cm/s, HR 2.2) and reduced GLS (HR 2.38). But not abnormal E/e' and LAE were associated with incident HF. Conclusions New echocardiographic parameters are useful in prediction of incident HF and should be added to standard SBHF criteria in asymptomatic patients with type 2 diabetes mellitus. Additional research is needed to update HF screening guidelines. Acknowledgement/Funding Supported by grant from the Slovak Society of Cardiology 2015 Selective screening of heart failure stages in regional settings

Empagliflozin in patient with heart failure and type 2 diabetes mellitus: new possibilities for drug therapy

2021 ◽  
Vol 1 (29) ◽  
pp. 8-12
Author(s):  
D. Yu. Sedykh ◽  
V. V. Kashtalap ◽  
O. L. Barbarash
Keyword(s):  
Diabetes Mellitus ◽  
Heart Failure ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Drug Therapy ◽  
Systolic Dysfunction ◽  
Practical Experience ◽  
Optimal Drug ◽  
Severe Comorbidity

The article demonstrates the practical experience of the effective use of inhibitor of sodium-glucose co-transporter 2 emplagliflozin as a part of optimal drug therapy in patients with decompensation of chronic heart failure with systolic dysfunction of ischemic genesis and type 2 diabetes mellitus. The place of this group of drugs in improving the quality of life and prognosis in patients with severe comorbidity has been indicated according to the data of evidence-based studies.

Abstract # P-15: Incremental Burden of Type 2 Diabetes Mellitus in Patients Hospitalized for Heart Failure

2016 ◽  
Vol 22 ◽  
pp. 20-21
Author(s):  
Aditya D. Raju ◽  
Anna D. Coutinho ◽  
Weijia Wang ◽  
Sharash Shetty ◽  
Stephen S. Sander ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Heart Failure ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus

1142-P: Comparison of Hospitalization for Heart Failure (HHF) among Patients with Type 2 Diabetes Mellitus (T2DM) and Macroalbuminuria Initiated on Canagliflozin (CANA) or a DPP-4

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 1142-P
Author(s):  
DOMINIC PILON ◽  
MICHAEL DURKIN ◽  
AMEUR MANCEUR ◽  
ISABELLE GHELERTER ◽  
MARIE-HÉL LAFEUILLE ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Heart Failure ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus

Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction

2019 ◽  
Vol 19 (20) ◽  
pp. 1818-1849 ◽  
Author(s):  
Ban Liu ◽  
Yuliang Wang ◽  
Yangyang Zhang ◽  
Biao Yan
Keyword(s):  
Diabetes Mellitus ◽  
Heart Failure ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Renal Dysfunction ◽  
Sglt2 Inhibitors ◽  
Sodium Glucose Cotransporter ◽  
Glucose Reabsorption ◽  
Renal Glucose Reabsorption

: Type 2 diabetes mellitus is one of the most common forms of the disease worldwide. Hyperglycemia and insulin resistance play key roles in type 2 diabetes mellitus. Renal glucose reabsorption is an essential feature in glycaemic control. Kidneys filter 160 g of glucose daily in healthy subjects under euglycaemic conditions. The expanding epidemic of diabetes leads to a prevalence of diabetes-related cardiovascular disorders, in particular, heart failure and renal dysfunction. Cellular glucose uptake is a fundamental process for homeostasis, growth, and metabolism. In humans, three families of glucose transporters have been identified, including the glucose facilitators GLUTs, the sodium-glucose cotransporter SGLTs, and the recently identified SWEETs. Structures of the major isoforms of all three families were studied. Sodium-glucose cotransporter (SGLT2) provides most of the capacity for renal glucose reabsorption in the early proximal tubule. A number of cardiovascular outcome trials in patients with type 2 diabetes have been studied with SGLT2 inhibitors reducing cardiovascular morbidity and mortality. : The current review article summarises these aspects and discusses possible mechanisms with SGLT2 inhibitors in protecting heart failure and renal dysfunction in diabetic patients. Through glucosuria, SGLT2 inhibitors reduce body weight and body fat, and shift substrate utilisation from carbohydrates to lipids and, possibly, ketone bodies. These pleiotropic effects of SGLT2 inhibitors are likely to have contributed to the results of the EMPA-REG OUTCOME trial in which the SGLT2 inhibitor, empagliflozin, slowed down the progression of chronic kidney disease and reduced major adverse cardiovascular events in high-risk individuals with type 2 diabetes. This review discusses the role of SGLT2 in the physiology and pathophysiology of renal glucose reabsorption and outlines the unexpected logic of inhibiting SGLT2 in the diabetic kidney.

GDF-15 and neutrophils in patients with heart failure and type 2 diabetes mellitus

2021 ◽  
Vol 28 (Supplement_1) ◽  
Author(s):  
AA Garganeeva ◽  
EA Kuzheleva ◽  
VA Fedyunina ◽  
VA Aleksandrenko
Keyword(s):  
Diabetes Mellitus ◽  
Heart Failure ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Inflammatory Marker ◽  
Study Groups ◽  
Significant Negative Correlation ◽  
Enzyme Linked Immunosorbent Assay ◽  
National Budget

Abstract Funding Acknowledgements Type of funding sources: Public grant(s) – National budget only. Main funding source(s): This study was funded by (subject of fundamental scientific research on a state assignment № АААА-А17-117052310073-6 от 23.05.2017 Introduction. Growth differentiation factor-15 (GDF-15) is a biomarker associated with inflammatory processes in the pathogenesis of chronic heart failure (CHF) which expresses in cardiomyocytes under pathological conditions. The relationship between the level of GDF-15 and type 2 diabetes mellitus (T2DM) has also been proven. It is necessary to study GDF-15 in patients with CHF and T2DM. Aim To investigate the association between serum GDF-15 levels in patients with CHF of ischemic etiology and the concentration of the main leukocyte fractions depending on presence or absence of T2DM. Material and methods. The study included 42 patients. The patients were divided into 2 groups. The first group consisted of patients with CHF and T2DM (n = 14). The second group  consisted of patients with CHF without T2DM (n = 28). Determination of GDF-15 concentration was carried out by enzyme-linked immunosorbent assay (BioVendor, Czech Republic). The absolute concentration of lymphocytes, neutrophils, as well as the ratio of neutrophils to lymphocytes in the blood were analyzed. Statistical analysis was performed using the Statistica software (v.10.0). The data were described as a median and interquartile range, the Mann-Whitney test was used to compare them. The correlation analysis was tested using the Spearman"s correlation coefficient. Results and discussion. The average level of the GDF-15 in the study groups was comparable: 2389 (2104; 3375) pg/ml and 2309 (2047; 3014) pg/ml in the first and second groups, respectively (p = 0.6). In the general cohort of CHF patients, the GDF-15 concentration was not correlate with the lymphocytes concentration (r = -0.001, p = 0.95), neutrophils (r = -0.14, p = 0.4) and the ratio of neutrophils to lymphocytes (r = -0.12, p = 0.25). At the same time, in the group of patients with T2DM, a significant negative correlation was revealed between the concentration of GDF-15 in the serum and the concentration of neutrophils (r = -0.6, p = 0.022). While both other analyzed parameters did not demonstrate significant correlations with GDF-15 (p &gt; 0.05). In the group of CHF patients without T2DM, no correlations were found between GDF-15 and the studied parameters, including neutrophils (r = 0.02, p = 0.3). Along with this the median of the neutrophils concentration did not vary among groups (3.5 (2.3; 5.3) vs 3.2 (2.7; 4.1) * 109 / l; p = 0.8). Conclusion The concentration of the inflammatory marker GDF-15 in the blood of patients with CHF in combination with T2DM correlates with the concentration of neutrophils. In the absence of T2DM, no significant correlations were found between GDF-15 and the main leukocyte fractions. The results obtained indicate the possible prospect of using the GDF-15 biomarker in a cohort of patients with CHF in combination with T2DM.

Sign in / Sign up

Export Citation Format

Share Document